MUSTOPHORAN IN THE TREATMENT OF MALIGNANT GLIOMAS: RESULTS OF PROSPECTIVE PILOT STUDY
The article presents results of study involving 32 patients with malignant gliomas, which has evaluated two regimen of chemotherapy: fotemustin (Mustophoran) as monotherapy in patients with anaplastic gliomas, and Mustophoran in combination with carboplatin and etoposide in patients with glioblastoma; hematological and other toxicity of chemotherapy regimens were also assessed. Based on these results, Mustophoran as monotherapy can be recommended as a priority regimen in the adjuvant treatment of patients with anaplastic gliomas III malignance grade.